These results highlight the potential of the synergistic effects of curcumin and gemcitabine, together with targeting the LAT2/glutamine pathway, as a promising strategy for the treatment of CCA and possibly other cancers. This evidence concerns the gene LAT2 and cholangiocarcinoma.